Immunohistochemical biomarkers for bladder cancer prognosis

International Journal of Urology

Volumn 18, Issue 9, 2011, Pages 616-629

  Matsushita, Kazuhito ^b   Cha, Eugene K ^a   Matsumoto, Kazumasa ^b   Baba, Shiro ^b   Chromecki, Thomas F ^a,c   Fajkovic, Harun ^a,d   Sun, Maxine ^e   Karakiewicz, Pierre I ^e   Scherr, Douglas S ^a   Shariat, Shahrokh F ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d General Hospital St Poelten   (Austria)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Bladder cancer; Marker; Molecular biology; Prediction; Prognosis; Survival

Indexed keywords

ANDROGEN RECEPTOR; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; CASPASE 3; CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FAS ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SURVIVIN; THROMBOSPONDIN 1; TUMOR MARKER; UROPLAKIN; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; BLADDER CANCER; CANCER RECURRENCE; CAPILLARY DENSITY; CARCINOGENESIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL DECISION MAKING; DNA REPLICATION; FOLLOW UP; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL; MICROVASCULATURE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SURGICAL TECHNIQUE; TRANSURETHRAL RESECTION; TUMOR SUPPRESSOR GENE; UROTHELIAL CARCINOMA OF THE BLADDER;

ANGIOGENIC PROTEINS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; HUMANS; IMMUNOHISTOCHEMISTRY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; RETINOBLASTOMA PROTEIN; RISK FACTORS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 80051870161     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2011.02809.x     Document Type: Review

References (123)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60: 277-300.
2. Stenzl A, Cowan NC, De Santis M etal. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur. Urol. 2009; 55: 815-25.
3. Kirkali Z, Chan T, Manoharan M etal. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66: 4-34.
4. Shariat SF, Karakiewicz PI, Palapattu GS etal. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J. Urol. 2006; 176: 2414-22.
5. Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer BG. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J. Urol. 2006; 176: 486-92.
6. Stein JP, Lieskovsky G, Cote R etal. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J. Clin. Oncol. 2001; 19: 666-75.
7. Donat SM. Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus reality. J. Natl Compr. Canc. Netw. 2009; 7: 40-7.
8. Bellmunt J, Hautmann RE. Open to debate. The motion: perioperative chemotherapy in muscle invasive bladder cancer improves survival. Eur. Urol. 2008; 54: 1192-7.
9. Shariat SF, Tilki D. Bladder cancer: nomogram aids clinical decision making after radical cystectomy. Nat. Rev. Urol. 2010; 7: 182-4.
10. Shariat SF, Margulis V, Karakiewicz PI. Rebuttal from authors re: James W.F. Catto. More nomograms or better evidence of efficacy: what do we need in urologic oncology? Eur Urol 2008;54:11-12. Eur. Urol. 2008; 54: 13-15.
11. Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr. Opin. Urol. 2008; 18: 1-8.
12. Shariat SF, Karakiewicz PI, Ashfaq R etal. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008; 112: 315-25.
13. Vrooman OP, Witjes JA. Molecular markers for detection, surveillance and prognostication of bladder cancer. Int. J. Urol. 2009; 16: 234-43.
14. Kim YK, Kim WJ. Epigenetic markers as promising prognosticators for bladder cancer. Int. J. Urol. 2009; 16: 17-22.
15. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-10.
16. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta 1998; 1378: F115-77.
17. Esrig D, Spruck CH 3rd, Nichols PW etal. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol. 1993; 143: 1389-97.
18. Cote RJ, Dunn MD, Chatterjee SJ etal. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 1998; 58: 1090-4.
19. Grossman HB, Liebert M, Antelo M etal. p53 and RB expression predict progression in T1 bladder cancer. Clin. Cancer Res. 1998; 4: 829-34.
20. Dalbagni G, Presti J, Reuter V, Fair WR, Cordon-Cardo C. Genetic alterations in bladder cancer. Lancet 1993; 342: 469-71.
21. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. Allelotype of human bladder cancer. Cancer Res. 1994; 54: 531-8.
22. Chatterjee SJ, Datar R, Youssefzadeh D etal. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J. Clin. Oncol. 2004; 22: 1007-13.
23. Shariat SF, Tokunaga H, Zhou J etal. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol. 2004; 22: 1014-24.
24. Malats N, Bustos A, Nascimento CM etal. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 2005; 6: 678-86.
25. Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod. Pathol. 2007; 20: 445-59.
26. Tokunaga H, Shariat SF, Green AE etal. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. Int. J. Radiat. Oncol. Biol. Phys. 2001; 51: 16-22.
27. Goebell PJ, Groshen SG, Schmitz-Dräger BJ on behalf of the ISBC. IS-IoBC p53 immunohistochemistry in bladder cancer: a new approach to an old question. Urol. Oncol. 2010; 28: 377-88.
28. Shariat SF, Lotan Y, Vickers A etal. Statistical consideration for clinical biomarker research in bladder cancer. Urol. Oncol. 2010; 28: 389-400.
29. Shariat SF, Chade DC, Karakiewicz PI etal. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J. Urol. 2010; 183: 68-75.
30. Shariat SF, Bolenz C, Karakiewicz PI etal. p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int. 2010; 105: 489-95.
31. Shariat SF, Weizer AZ, Green A etal. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology 2000; 56: 735-40.
32. Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 2003; 61: 1140-5.
33. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum. Pathol. 2006; 37: 1568-76.
34. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J. Urol. 2007; 177: 481-7.
35. Shariat SF, Bolenz C, Godoy G etal. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J. Urol. 2009; 182: 78-84.
36. Shariat SF, Lotan Y, Karakiewicz PI etal. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J. Urol. 2009; 182: 907-13.
37. Lamy A, Gobet F, Laurent M etal. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J. Urol. 2006; 176: 2686-9.
38. Stern MC, Conway K, Li Y, Mistry K, Taylor JA. DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer. Mol. Carcinog. 2006; 45: 715-19.
39. Ryk C, Kumar R, Sanyal S etal. Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours. Cancer Lett. 2006; 241: 142-9.
40. Lopez-Knowles E, Hernandez S, Kogevinas M etal. The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin. Cancer Res. 2006; 12: 6029-36.
41. Moonen PM, van Balken-Ory B, Kiemeney LA, Schalken JA, Witjes JA. Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. J. Urol. 2007; 177: 80-3.
42. Esuvaranathan K, Chiong E, Thamboo TP etal. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer 2007; 109: 1097-105.
43. Dalbagni G, Parekh DJ, Ben-Porat L, Potenzoni M, Herr HW, Reuter VE. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int. 2007; 99: 281-5.
44. Yurakh AO, Ramos D, Calabuig-Farinas S etal. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur. Urol. 2006; 50: 506-15.
45. Stein JP, Ginsberg DA, Grossfeld GD etal. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl Cancer Inst. 1998; 90: 1072-9.
46. 1-phase progression. Genes Dev. 1999; 13: 1501-12.
47. Schrier BP, Vriesema JL, Witjes JA, Kiemeney LA, Schalken JA. The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma. Eur. Urol. 2006; 50: 76-82.
48. Richter J, Wagner U, Kononen J etal. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am. J. Pathol. 2000; 157: 787-94.
49. Del Pizzo JJ, Borkowski A, Jacobs SC, Kyprianou N. Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am. J. Pathol. 1999; 155: 1129-36.
50. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J. Cell Physiol. 2009; 220: 292-6.
51. Reed JC. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 1999; 17: 2941-53.
52. McKnight JJ, Gray SB, O'Kane HF, Johnston SR, Williamson KE. Apoptosis and chemotherapy for bladder cancer. J. Urol. 2005; 173: 683-90.
53. Nagata S. Apoptosis by death factor. Cell. 1997; 88: 355-65.
54. Svatek RS, Herman MP, Lotan Y etal. Soluble Fas-A promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 2006; 106: 1701-7.
55. Yamana K, Bilim V, Hara N etal. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br. J. Cancer 2005; 93: 544-51.
56. Arai M, Sasaki A, Saito N, Nakazato Y. Immunohistochemical analysis of cleaved caspase-3 detects high level of apoptosis frequently in diffuse large B-cell lymphomas of the central nervous system. Pathol. Int. 2005; 55: 122-9.
57. Giannopoulou I, Nakopoulou L, Zervas A etal. Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications. Urol. Res. 2002; 30: 342-5.
58. Burton PB, Anderson CJ, Corbishly CM. Caspase 3 and p27 as predictors of invasive bladder cancer. N. Engl. J. Med. 2000; 343: 1418-20.
59. Karam JA, Lotan Y, Karakiewicz PI etal. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 2007; 8: 128-36.
60. Ong F, Moonen LM, Gallee MP etal. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother. Oncol. 2001; 61: 169-75.
61. Kong G, Shin KY, Oh YH etal. Bcl-2 and p53 expressions in invasive bladder cancers. Acta Oncol. 1998; 37: 715-20.
62. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997; 3: 917-21.
63. Akhtar M, Gallagher L, Rohan S. Survivin: role in diagnosis, prognosis, and treatment of bladder cancer. Adv. Anat. Pathol. 2006; 13: 122-6.
64. Salz W, Eisenberg D, Plescia J etal. A survivin gene signature predicts aggressive tumor behavior. Cancer Res. 2005; 65: 3531-4.
65. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22: 8581-9.
66. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am. J. Pathol. 1998; 152: 43-9.
67. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Alterieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001; 285: 324-8.
68. Shariat SF, Casella R, Khoddami SM etal. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J. Urol. 2004; 171: 626-30.
69. Schultz IJ, Kiemeney LA, Karthaus HF etal. Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin. Chem. 2004; 50: 1425-8.
70. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007; 109: 1106-13.
71. Shariat SF, Karakiewicz PI, Godoy G etal. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin. Cancer Res. 2009; 15: 7012-19.
72. Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J. Urol. 2008; 26: 59-65.
73. Bochner BH, Cote RJ, Weidner N etal. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J. Natl Cancer Inst. 1995; 87: 1603-12.
74. Inoue K, Slaton JW, Karashima T etal. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin. Cancer Res. 2000; 6: 4866-73.
75. Streeter EH, Harris AL. Angiogenesis in bladder cancer: prognostic marker and target for future therapy. Surg. Oncol. 2002; 11: 85-100.
76. Shariat SF, Youssef RF, Gupta A etal. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J. Urol. 2010; 183: 1744-50.
77. Jaeger TM, Weidner N, Chew K etal. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J. Urol. 1995; 154: 69-71.
78. Wang JM, Kumar S, Pye D, Haboubi N, al-Nakib L. Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers. J. Natl Cancer Inst. 1994; 86: 386-8.
79. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-4.
80. Grossfeld GD, Ginsberg DA, Stein JP etal. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J. Natl Cancer Inst. 1997; 89: 219-27.
81. Zu X, Tang Z, Li Y, Gao N, Ding J, Qi L. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int. 2006; 98: 1090-3.
82. Miyata Y, Kanda S, Ohba K etal. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D. Clin. Cancer Res. 2006; 12: 800-6.
83. Elfiky AA, Rosenberg JE. Targeting angiogenesis in bladder cancer. Curr. Oncol. Rep. 2009; 11: 244-9.
84. Xia G, Kumar SR, Hawes D etal. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J. Urol. 2006; 175: 1245-52.
85. Chodak GW, Hospelhorn V, Judge SM, Mayforth R, Koeppen H, Sasse J. Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res. 1988; 48: 2083-8.
86. Watanabe H, Hori A, Seno M etal. A sensitive enzyme immunoassay for human basic fibroblast growth factor. Biochem. Biophys. Res. Commun. 1991; 175: 229-35.
87. Miyake H, Hara I, Gohji K, Yoshimura K, Arakawa S, Kamidono S. Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett. 1998; 123: 121-6.
88. Moll R, Wu XR, Lin JH, Sun TT. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am. J. Pathol. 1995; 147: 1383-97.
89. Huang HY, Shariat SF, Sun TT etal. Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. Hum. Pathol. 2007; 38: 1703-13.
90. Neal DE, Marsh C, Bennett MK etal. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985; 1: 366-8.
91. MacLaine NJ, Wood MD, Holder JC, Rees RW, Southgate J. Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway. Mol. Cancer Res. 2008; 6: 53-63.
92. Mellon K, Wright C, Kelly P, Horne CH, Neal DE. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J. Urol. 1995; 153: 919-25.
93. Kassouf W, Luongo T, Brown G, Adam L, Dinney CP. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J. Urol. 2006; 176: 787-92.
94. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int. 2008; 101: 20-5.
95. Paez JG, Jänne PA, Lee JC etal. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
96. Blehm KN, Spiess PE, Bondaruk JE etal. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin. Cancer Res. 2006; 12: 4671-7.
97. Villares GJ, Zigler M, Blehm K etal. Targeting EGFR in bladder cancer. World J. Urol. 2007; 25: 573-9.
98. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005; 24: 5218-25.
99. Aveyard JS, Skilleter A, Habuchi T, Knowles MA. Somatic mutation of PTEN in bladder carcinoma. Br. J. Cancer 1999; 80: 904-8.
100. Lopez-Knowles E, Hernandez S, Malats N etal. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res. 2006; 66: 7401-4.
101. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006; 7: 606-19.
102. Fan QW, Knight ZA, Goldenberg DD etal. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell. 2006; 9: 341-9.
103. Knowles MA. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J. Urol. 2007; 25: 581-93.
104. Lindgren D, Liedberg F, Andersson A etal. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006; 25: 2685-96.
105. Zieger K, Dyrskjot L, Wiuf C etal. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin. Cancer Res. 2005; 11: 7709-19.
106. Kassouf W, Black PC, Tuziak T etal. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J. Urol. 2008; 179: 353-8.
107. Jimenez RE, Hussain M, Bianco FJ Jr etal. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin. Cancer Res. 2001; 7: 2440-7.
108. Mellon JK, Lunec J, Wright C, Horne CH, Kelly P, Neal DE. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J. Urol. 1996; 155: 321-6.
109. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin. Cancer Res. 2001; 7: 1957-62.
110. Liedberg F, Anderson H, Chebil G etal. Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol. Oncol. 2008; 26: 17-24.
111. Gandour-Edwards R, Lara PN Jr, Folkins AK etal. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 2002; 95: 1009-15.
112. Kruger S, Weitsch G, Buttner H etal. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int. J. Cancer 2002; 102: 514-18.
113. Sato K, Moriyama M, Mori S etal. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 1992; 70: 2493-8.
114. Kolla SB, Seth A, Singh MK etal. Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int. Urol. Nephrol. 2008; 40: 321-7.
115. Bolenz C, Shariat SF, Karakiewicz PI etal. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int. 2010; 106: 1216-22.
116. Boorjian S, Ugras S, Mongan NP etal. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 2004; 64: 383-8.
117. Tuygun C, Kankaya D, Imamoglu A etal. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol. Oncol. 2011; 29: 43-51.
118. Mir C, Shariat SF, Van Der Kwast TH etal. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int. 2011; 108: 24-30.
119. Bolenz C, Lotan Y, Ashfaq R, Shariat SF. Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. Eur. Urol. 2009; 56: 1093-5.
120. Shen SS, Smith CL, Hsieh JT etal. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006; 106: 2610-16.
121. Basakci A, Kirkali Z, Tuzel E, Yorukoglu K, Mungan MU, Sade M. Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder. Eur. Urol. 2002; 41: 342-5.
122. Cordon-Cardo C, Zhang ZF, Dalbagni G etal. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res. 1997; 57: 1217-21.
123. Shariat SF, Karakiewicz PI, Ashfaq R etal. Combination of cell cycle regulating bio-markers improves prognosis in patients with organ-confined urothelial carcinoma at radical cystectomy. J. Urol. 2008; 179: 578.